<DOC>
	<DOCNO>NCT00553696</DOCNO>
	<brief_summary>To assess maximal tolerate dose ( MTD ) overall safety sunitinib administer combination S-1 Cisplatin patient advanced/metastatic gastric cancer .</brief_summary>
	<brief_title>Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis gastric cancer Chemonaive patient Adequate organ function Patients meet contraindication S1 Cisplatin . Prior chemotherapy failure patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>combination</keyword>
</DOC>